Targeted Therapies in Older Adults With Solid Tumors.

Abstract

Article Tools REVIEW ARTICLES Caring for Older Adults With Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.21.00132 Journal of Clinical Oncology - published online before print May 27, 2021 PMID: 34043448 Targeted Therapies in Older Adults With Solid Tumors Nicolò Matteo Luca Battisti , MD1xNicolò Matteo Luca BattistiSearch for articles by this author; Lore Decoster , MD, PhD2xLore DecosterSearch for articles by this author; Grant R. Williams , MD, MSPH3xGrant R. WilliamsSearch for articles by this author; Ravindran Kanesvaran , MD4xRavindran KanesvaranSearch for articles by this author; Hans Wildiers , MD, PhD5,6xHans WildiersSearch for articles by this author; and Alistair Ring, MA, MD1xAlistair RingSearch for articles by this author Show More 1Department of Medicine—Breast Unit, The Royal Marsden NHS Foundation Trust, Breast Cancer Research Division, The Institute of Cancer Research, Surrey, United Kingdom2Department of Medical Oncology, Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium3Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham School of Medicine, Birmingham, AL4Division of Medical Oncology, National Cancer Centre Singapore, Singapore5Department of General Medical Oncology and Multidisciplinary Breast Centre, University Hospitals Leuven, Leuven Cancer Institute, Laboratory of Experimental Oncology, Leuven, Belgium6Department of Oncology, KU Leuven, Leuven, Belgium https://doi.org/10.1200/JCO.21.00132 First Page Full Text PDF Figures and Tables Supplements © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveAre targeted agents safe and effective systemic treatment options for older adults with solid tumors?Knowledge GeneratedOlder individuals represent a significant proportion of patients with cancer. However, evidence regarding the efficacy and safety of most monoclonal antibodies, antibody-drug conjugates, and small molecules are very limited in the older population. These evidence gaps may lead to incorrect assumptions regarding safety, side effects, and efficacy. This may mean that potentially beneficial treatments are withheld owing to concerns regarding lack of supportive evidence. Conversely, older patients may be exposed to undue risk of side effects owing to underestimates of toxicity.RelevanceThis review highlights data gaps. It is critical for the oncology community that investigators and regulatory authorities are aware of these issues, such that they can be addressed for the benefit of older patients with cancer.SUPPORTG.W. is supported in part by the National Cancer Institute of the National Institutes of Health (K08CA234225).AUTHOR CONTRIBUTIONSConception and design: Nicolò Matteo Luca Battisti, Lore Decoster, Grant R. Williams, Alistair RingCollection and assembly of data: Nicolò Matteo Luca Battisti, Grant R. Williams, Ravindran Kanesvaran, Hans Wildiers, Alistair RingData analysis and interpretation: Nicolò Matteo Luca Battisti, Lore Decoster, Grant R. Williams, Ravindran Kanesvaran, Hans Wildiers, Alistair RingManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTTargeted Therapies in Older Adults With Solid TumorsThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).No potential conflicts of interest were reported.